Cyclo Therapeutics, Inc. (CYTH)

1.2900 -0.0400 (-3.05%) As of 02:26PM EDT. Market open.

Cyclo Therapeutics, Inc.

6714 NW 16th Street
Suite B
Gainesville, FL 32653
United States
386 418 8060
https://cyclotherapeutics.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 8

Key executives

Name	Title	Pay	Exercised	Year born
Mr. N. Scott Fine	CEO & Director	569.92k	N/A	1957
Mr. C. E Strattan	Founder & Director	N/A	N/A	1946
Mr. Joshua M. Fine	CFO & Secretary	421.17k	N/A	1982
Mr. Michael Eric Lisjak	Global Head of Regulatory Affairs & Senior VP of Business Development	430.4k	N/A	1974
Dr. Jeffrey L. Tate Ph.D.	COO, Chief Quality Officer & Director	255.14k	N/A	1958
Ms. Lori McKenna	Global Head of Patient Advocacy	N/A	N/A	N/A
Dr. Karen Mullen FFPM	Interim Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

Corporate governance

Cyclo Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.